Ajooni Biotech Ltd. Appoints Ishtneet Bhatia as Independent Director

Mohali, Punjab | February 5, 2025 – Ajooni Biotech Limited has announced the regularization of Mr. Ishtneet Bhatia’s appointment as an Independent Director of the company. The decision was formally approved by shareholders at the 1st Extraordinary General Meeting (EGM) held on February 3, 2025, through video conferencing.

Key Details of the Appointment​

• Position: Independent Director
• Tenure: Five years (effective from January 3, 2025)
• Retirement: Not liable to retire by rotation
• Approval Process: Special resolution passed at the EGM

The voting results, along with the scrutinizer's report, were officially declared on September 4, 2025, confirming shareholder approval for Bhatia’s appointment.

Strategic Implications​

This move is expected to strengthen Ajooni Biotech’s corporate governance framework, bringing additional independent oversight to the company’s strategic direction. The appointment aligns with the company’s compliance with SEBI’s Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Ajooni Biotech's Managing Director, Jasjot Singh, signed the official filing to the National Stock Exchange of India Ltd. (NSE).

For further updates, investors are encouraged to refer to official filings on the company’s website or the NSE platform.